Leerink Partnrs Weighs in on Replimune Group Q3 Earnings

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Stock analysts at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for Replimune Group in a note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings per share of ($0.71) for the quarter, down from their previous forecast of ($0.64). The consensus estimate for Replimune Group's current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for Replimune Group's Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.82) EPS and FY2026 earnings at ($2.25) EPS.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.07.

REPL has been the subject of a number of other reports. Roth Capital upgraded Replimune Group to a "strong-buy" rating in a research report on Tuesday, August 27th. HC Wainwright restated a "buy" rating and set a $17.00 price objective on shares of Replimune Group in a research report on Tuesday. JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 24th. Finally, Roth Mkm initiated coverage on Replimune Group in a research report on Tuesday, August 27th. They set a "buy" rating and a $17.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $16.80.

Replimune Group Price Performance

REPL stock traded down $0.63 during trading hours on Friday, hitting $10.77. 336,307 shares of the stock traded hands, compared to its average volume of 1,032,731. The stock has a 50-day simple moving average of $11.44 and a 200 day simple moving average of $9.50. Replimune Group has a one year low of $4.92 and a one year high of $12.97. The company has a market cap of $736.88 million, a P/E ratio of -3.74 and a beta of 1.19. The company has a current ratio of 10.11, a quick ratio of 13.46 and a debt-to-equity ratio of 0.18.

Institutional Trading of Replimune Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REPL. Millennium Management LLC raised its stake in shares of Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock valued at $28,062,000 after buying an additional 2,656,173 shares in the last quarter. Braidwell LP raised its stake in shares of Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company's stock valued at $33,656,000 after acquiring an additional 2,057,460 shares during the last quarter. Baker BROS. Advisors LP grew its position in Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock worth $121,057,000 after acquiring an additional 1,000,000 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company's stock worth $53,505,000 after purchasing an additional 699,679 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its stake in shares of Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company's stock valued at $8,371,000 after buying an additional 238,747 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.